Joint pain injections provide faster relief from severe pain and reduce inflammation of joints. Several types of injections available in the market include corticosteroids injections, hyaluronic acid (HA) injections, platelet-rich plasma (PRP) injections, and placental tissue matrix (PTM) injections. The growth of the joint pain injection market is attributed to the factors such as high prevalence of musculoskeletal disorders and increasing number of sports injuries. However, high costs of joint repair therapies hinder the market growth
Musculoskeletal disorders are medical conditions affecting muscles, bones, and joints of neck, shoulders, wrists, back, hips, legs, knees, and feet. These diseases include tendinitis, carpal tunnel syndrome, osteoarthritis, rheumatoid arthritis (RA), fibromyalgia, and bone fractures. As per the World Health Organization (WHO) factsheet updated in 2018, musculoskeletal conditions are the second-largest contributor to disability worldwide. According to the same, the prevalence and impact of musculoskeletal disorders is expected to rise with the increase in aging population and rise in the prevalence of risk factors of noncommunicable diseases (NCDs) worldwide. As per 2016 American Academy of Orthopedic Surgeons’ annual meeting data, ~1 in 2 adults is suffering from a musculoskeletal disorder in the US. Further, according to the Centers for Disease Control and Prevention (CDC), arthritis causes severe pain that affects millions of people in the US every year. Around one in four arthritis patients, i.e., ~15 million of total ~54 million patients, experiences severe arthritis-related joint pain.
Further, osteoarthritis (OA) is one of the most common joint disorders in the US, caused by the breakdown of joint cartilage between bones. It is also known as degenerative joint disease or “wear and tear” arthritis. As per the Centers for Disease Control and Prevention (CDC), more than 32.5 million adults in the US suffer from osteoarthritis. Similarly, as per the National Health Service (NHS), more than 10 million people in the UK have arthritis or other similar conditions that affect joints. As per the Bupa Health Insurance, osteoarthritis is the most common form of arthritis prevalent in the UK, it affects around the one-third of people aged 45 or more in the country, i.e., ~8.75 million people. Therefore, such high prevalence of musculoskeletal disorders in different countries is increasing the number of treatment procedures being carried out for the same, thereby driving the joint pain injection market growth.
The joint pain injection market, by drug, is segmented into hyaluronic acid, corticosteroid, and others. The corticosteroid segment held the largest share of the market in 2020, and it is further anticipated to register the highest CAGR during the forecast period.
Based on joint type, the joint pain injection market is segmented into knee, foot and ankle, shoulder and elbow, hips, and other applications. The knee segment held the largest market share in 2020 and is anticipated to register the highest CAGR in the market during the forecast period.
The regional trends and factors influencing the Joint Pain Injection Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Joint Pain Injection Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2020 | US$ 3.67 Billion |
| Market Size by 2028 | US$ 7 Billion |
| Global CAGR (2020 - 2028) | 8.5% |
| Historical Data | 2018-2019 |
| Forecast period | 2021-2028 |
| Segments Covered |
By Drug
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Joint Pain Injection Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Joint Pain Injection Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
Based on distribution channel, the joint pain injection market is segmented into retail pharmacies, hospitals pharmacies, and others. The wound care segment held the largest market share in 2020, and the bone grafts segment is estimated to register the highest CAGR in the market during the forecast period.
Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the joint pain injection market players focus on the collaboration strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name globally.
The List of Companies - Joint Pain Injection Market
The joint pain injection market majorly consists of the players such as Chugai Pharmaceutical Co., Ltd., Teva Pharmaceuticals, Bioventus Inc., Fidia Pharma USA Inc., Flexion Therapeutics, Inc., SEIKAGAKU CORPORATION, Ferring B.V., Sanofi, Anika Therapeutics, Inc., and OrthogenRx among others.
The global joint pain injection market growth is mainly attributed to factors such the high prevalence of musculoskeletal disorders and increasing number of sports injuries. However, the high costs of joint repair therapies hinder the market growth.
Joint pain injections are medicinal fluids inserted in the patient’s body to get faster relief from severe pain. The joint pain injections are used to reduce inflammation in the joints. There are several types of injections available in the market which are corticosteroids injections, hyaluronic acid (HA) injections, platelet-rich plasma (PRP) injections and placental tissue matrix (PTM) injections.